日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials.

推进胶质母细胞瘤的临床反应:在临床前模型中评估 SHP1705 CRY2 激活剂的疗效,并在 I 期试验中评估其安全性

Chan Priscilla, Nagai Yoshiko, Wu Qiulian, Hovsepyan Anahit, Mkhitaryan Seda, Wang Jiarui, Karapetyan Gevorg, Kamenecka Theodore, Solt Laura A, Cope Jamie, Moats Rex A, Hirota Tsuyoshi, Rich Jeremy N, Kay Steve A

A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload

一项评估BBI-001(一种用于治疗铁过载的非吸收性口服药物)的1b期随机临床试验正在进行中。

Scribner, Curtis; Cope, Jamie; Ryan, Philip; Olynyk, John K; Ryan, John; Griffin, J Daniel; Berkland, Cory

CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy.

CRY2 亚型选择性昼夜节律调节剂对胶质母细胞瘤的疗效

Miller Simon, Kesherwani Manish, Chan Priscilla, Nagai Yoshiko, Yagi Moeri, Cope Jamie, Tama Florence, Kay Steve A, Hirota Tsuyoshi

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen

葡萄糖基脂质 A 佐剂可显著增强 DNA-MVA-蛋白质疫苗方案引起的 HIV 特异性 T 细胞和 B 细胞反应

Paul F McKay, Alethea V Cope, Jamie F S Mann, Sarah Joseph, Mariano Esteban, Roger Tatoud, Darrick Carter, Steven G Reed, Jonathan Weber, Robin J Shattock